[Parkinson's disease].
C
C
Masson
D000328:Adult; D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D002396:Catechols / Q000627:therapeutic use; D003866:Depressive Disorder / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology; D003937:Diagnosis, Differential; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D020961:Lewy Body Disease / Q000175:diagnosis; D018696:Neuroprotective Agents / Q000627:therapeutic use; D009570:Nitriles; D010300:Parkinson Disease / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D020734:Parkinsonian Disorders / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy; D010479:Pergolide / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy / Q000209:etiology; D013997:Time Factors
D000978:Antiparkinson Agents; D002396:Catechols; D015259:Dopamine Agents; D018491:Dopamine Agonists; D007211:Indoles; D018696:Neuroprotective Agents; D009570:Nitriles; C046649:ropinirole; D010479:Pergolide; D007980:Levodopa; C071192:entacapone